| Literature DB >> 18667083 |
Dan Li1, Liang Chen, Xian Ding, Ran Tao, Yong Xin Zhang, Jie Fei Wang.
Abstract
BACKGROUND: Invasive pulmonary aspergillosis (IPA) is a rapid, progressive, fatal disease that occurs mostly in immunocompromised patients. Patients with severe liver disease are at a heightened risk for infections. Little is known about the clinical presentation including predisposing factors and treatment of IPA in patients with hepatic failure.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18667083 PMCID: PMC2516516 DOI: 10.1186/1471-230X-8-32
Source DB: PubMed Journal: BMC Gastroenterol ISSN: 1471-230X Impact factor: 3.067
Demographic features of 12 patients with IPA
| Characteristic | Number of patients |
| Age in years (mean ± S.D.) | 41.9 ± 9.5 |
| Males (%) | 87.5 |
| Disease onset | |
| Acute hepatic failure | 0 |
| Subacute hepatic failure | 3 |
| Chronic hepatic failure | 9 |
| Complications | |
| Hepatic encephalopathy | 5 |
| Hepatorenal syndrome | 3 |
| Spontaneous bacterial peritonitis | 3 |
| MELD score (median, range) | 30 (22–51) |
| Antibiotic usage | |
| Duration (days, mean ± S.D.) | 23.1 ± 8.6 |
| One antibiotic | 5 |
| Two antibiotics | 4 |
| Three or more antibiotics | 3 |
| Steroid exposure | 9 |
Clinical and laboratory parameters of patients with IPA
| Signs or symptoms | Number of patients |
| Fever | 12 |
| Cough | 3 |
| Chest pain | 0 |
| Hemoptysis | 0 |
| Crackles | 1 |
| Changes in bilateral lung fields | 9 |
| Bilateral lung fields diffused | 2 |
| Right unilateral lung | 2 |
| Left upper lobe | 4 |
| Halo and air-crescent | 2 |
| Hemoglobin (g/L, mean ± S.D.) | 95.7 ± 15.9 |
| Leukocyte counts (×10 9/L, mean ± S.D.) | 11.6 ± 7.9 |
| Neutrophils (%, mean ± S.D.) | 81.2 ± 6.4 |
| Thrombocyte count (×109/L, mean ± S.D.) | 102.7 ± 69.5 |
| Total bilirubin (μmol/L, mean ± S.D.) | 661.3 ± 189.7 |
| Prothrombin activity (%, range) | 8–26 |
| HBV viral load (copies/ml, range) | 104–107 |
Clinical features of patients with confirmed IPA
| Age/gender | Cause of HF | MELD score | Complications of HF | Co-morbid conditions | Outcome |
| 32/M | HBV | 37.12 | HE | PE | Recovered |
| 44/M | HBV | 29.16 | HRS | PE | Recovered |
| 38/M | HBV | 31.78 | HE | AP | Recovered |
| 51/F | HBV | 32.66 | PE | Recovered but paralyzed | |
| 64/M | HBV, HDV | 35.01 | HRS | PE | Recovered |
| 47/M | HBV | HE | Recovered | ||
| 39/M | HBV | 38.97 | SBP, HRS, HE | Dead | |
| 52/M | HBV | 33.14 | DM | Recovered | |
| 41/M | HBV | 30.63 | PE | Recovered |
MELD: model for end liver disease; PE: plasma exchange; HF: hepatic failure; HBV: hepatitis B virus; HDV: hepatitis D virus; HE: hepatic encephalopathy; HRS: hepatorenal syndrome; DM: diabetes mellitus; SBP: spontaneous bacterial peritonitis; AP: acute pancreatitis.